Prognosis depends on several factors, including performance status, duration of established paraplegia, and number of sites of metastasis at presentation, as well as the primary cancer and the patient's life expectancy before the development of MSCC.[7]Al-Qurainy R, Collis E. Metastatic spinal cord compression: diagnosis and management. BMJ. 2016 May 19;353:i2539.
http://www.ncbi.nlm.nih.gov/pubmed/27199232?tool=bestpractice.com
Longer duration of ambulation loss and more severe neurological deficit (e.g., muscle weakness, bladder and bowel dysfunction) are associated with lower probability of recovery of ambulation and neurological recovery in patients with symptomatic MSCC.[93]Laufer I, Zuckerman SL, Bird JE, et al. Predicting neurologic recovery after surgery in patients with deficits secondary to MESCC: systematic review. Spine (Phila Pa 1976). 2016 Oct 15;41 Suppl 20:S224-S230.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581189
http://www.ncbi.nlm.nih.gov/pubmed/27488300?tool=bestpractice.com
[94]Liu YH, Hu YC, Yang XG, et al. Prognostic factors of ambulatory status for patients with metastatic spinal cord compression: a systematic review and meta-analysis. World Neurosurg. 2018 Aug;116:e278-e290.
http://www.ncbi.nlm.nih.gov/pubmed/29733989?tool=bestpractice.com
Reports of recurrence rates of MSCC vary. This may depend, at least in part, on treatment modality. For example, radiotherapy after surgery reduces local recurrence compared with surgery alone, and longer-course radiotherapy schedules may be associated with lower in-field recurrence than short-course schedules.[7]Al-Qurainy R, Collis E. Metastatic spinal cord compression: diagnosis and management. BMJ. 2016 May 19;353:i2539.
http://www.ncbi.nlm.nih.gov/pubmed/27199232?tool=bestpractice.com